Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dyanavel XR in Children with ADHD
NCT03088267Phase 3Completed
- Sponsor
- Tris Pharma
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amphetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Tris Pharma. Started Feb 2017; status: completed.
02
Drugs
amphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03088267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088267.